Non-invasive prenatal test findings in 41,819 pregnant women: results from a clinical laboratory in southern China
- 5 January 2023
- journal article
- review article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 308 (3) , 787-795
Abstract
Background This paper evaluated the clinical utility of massively parallel sequencing-based non-invasive prenatal testing (NIPT) for detecting trisomy 21 (T21), T18, T13, sex chromosome aneuploidies (SCA), and rare chromosome aneuploidies (RCA) among the data collected by a clinical laboratory in southern China. Methods In a 3-year period between January 2017 and December 2019, over 40,000 pregnant women underwent NIPT clinical screening test for fetal T21, T18, T13, SCA, and RCA in our laboratory. NIPT samples were processed using the NextSeq CN500 platform. The positive results were confirmed by karyotyping, and chromosomal microarray analysis (CMA) or copy number variants (CNV) sequencing. Details of the pregnancy outcomes were collected via telephone interview. Results NIPT results were available for 41,819 cases; 691 positive cases were reported. The overall sensitivity for detection of T21, T18, T13, SCA, and RCA was 99.21, 100.00, 100.00, 98.55, and 100.00%, and the specificity was 99.95, 99.94, 99.98, 99.69, and 99.92%, respectively. The positive predictive values (PPVs) for detection of T21, T18, T13, SCA, and RCA were 85.62, 45.24, 40.00, 34.17, and 13.51%, respectively, and those for detection of 45,X, 47,XXY, 47,XXX, 47,XYY, and 46,XY(delX) 20.00, 59.18, 28.95, 61.54, and 25.00%, respectively. Regarding pregnancy outcomes, 92.38% of the pregnancies with confirmed aneuploidies were terminated, and 91.20% of those identified as having a false-positive result were carried to term. Among 252 unconfirmed cases, 24.60% of the pregnancies were terminated and 38.10% carried to term, while 37.30% declined interview. Conclusions NIPT is widely used to screen fetal aneuploidies based on its high sensitivity and specificity. However, in this study, the PPVs of NIPT in terms of detecting T18, T13, XO, XXX and RCA were < 50%. In addition, more than one-third of NIPT-positive women did not accept invasive prenatal diagnosis. Confirmatory diagnosis is strongly recommended for women with positive NIPT outcomes before any further decision is made.Keywords
All Related Versions
Funding Information
- Science and Technology Planning Project of Guangzhou, China (201604020104)
This publication has 22 references indexed in Scilit:
- Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromesGenetics in Medicine, 2019
- Prenatal cell‐free DNA screening for fetal aneuploidy in pregnant women at average or high risk: Results from a large US clinical laboratoryMolecular Genetics & Genomic Medicine, 2019
- New medical risks affecting obstetrics after implementation of the two-child policy in ChinaFrontiers of Medicine, 2017
- Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and GenomicsGenetics in Medicine, 2016
- Cell-free DNA Analysis for Noninvasive Examination of TrisomyNew England Journal of Medicine, 2015
- Maternal X chromosome copy number variations are associated with discordant fetal sex chromosome aneuploidies detected by noninvasive prenatal testingClinica Chimica Acta, 2015
- Maternal Mosaicism Is a Significant Contributor to Discordant Sex Chromosomal Aneuploidies Associated with Noninvasive Prenatal TestingClinical Chemistry, 2014
- Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasmaProceedings of the National Academy of Sciences, 2008
- X chromosome loss and ageingCytogenetic and Genome Research, 2007
- Presence of fetal DNA in maternal plasma and serumThe Lancet, 1997